Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00
VRTX logo

Vertex Hits $2.99 Billion in Q1 Revenue as Non-CF Products Drive 25% of Growth

VRTX8-KFiling Date: 5/4/2026
Vertex Pharmaceuticals Incorporated
Description

What this story covers

Vertex Pharmaceuticals reported $2.99 billion in Q1 2026 revenue, an 8% increase driven by its dominant cystic fibrosis franchise and successful launches in gene therapy and pain management. The company reaffirmed its $13 billion full-year revenue guidance.

Story snapshot

CompanyVertex Pharmaceuticals Incorporated
TickerVRTX
VariantStandard detailed
Duration0:00
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000875320-26-000171
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in